Cadila Healthcare

Cadila Pharmaceuticals said Aciloc 150+ and Aciloc 300+ remain available without any restrictions on manufacture or sale, while reaffirming compliance with regulatory requirements

The Maharashtra Food and Drug Administration (FDA) has barred the sale and distribution of some medicines manufactured by Cadila Pharmaceuticals Ltd and seized stock worth about Rs 2.45 crore across the state over branding similarities despite having different active pharmaceutical ingredients (APIs), officials said on Saturday. The order is linked to Aciloc 150, Aciloc 150 Plus, Aciloc 300 and Aciloc 300 Plus, which have Ranitidine and Famotidine as APIs, they said. The FDA has directed the company to immediately recall all available stocks of Aciloc 150, Aciloc 150 Plus, Aciloc 300 and Aciloc 300 Plus from the market over concerns that such branding could lead to medication errors. It has also barred the sale of Aciloc 150 Plus and Aciloc 300 Plus. "Any confusion caused by a medicine's brand name that could result in doctors, pharmacists or patients receiving the wrong drug is a serious public health concern," FDA Commissioner Tukaram Mundhe said in a statement. He said complianc

Cadiflu Tetra is developed employing Nano-sized particles, the Vaccine mimics the external structure of the virus without containing intact genetic material

The drug firm, earlier known as Cadila Healthcare, has fixed July 15, 2022 as the last date for the settlement of bids on stock exchanges which may even happen early, as per a regulatory filing.

Zydus to conduct mixing trials to test vax efficacy after two shots of Covishield/Covaxin

TCS is likely to announce results after market hours on Monday. The IT stocks will be in focus with Infosys too to announce earnings later this week.

The three-dose vaccine, named as 'ThRabis', is a recombinant nano-particle based G protein vaccine which is prepared using Virus-like Particle technology

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma

Apollo Hospitals is likely to be in limelight as the stock enters Nifty 50. It will be replacing IOC with effect from March 31.

Unveils 'innovation and care' centric corporate brand identity

Zydus, being one of the first applicants for Roflumilast Tablets, 500 mcg, is eligible for 180 days of shared generic drug exclusivity

BoI, Devyani Intl, Eveready, FSL, Mahindra Life, Paytm, REC, Siemens, Sintex, SPARC, Tata Steel, Thermax and Vijaya Diagnostics are some of the prominent companies to announce results today.

Revenue from operations nearly flat at Rs 3,655 crore in reporting quarter

Adani Green, Apollo Tyres, Adani Total Gas, Balrampur Chini, Dabur, eClerx, HDFC, IOB, Jubilant Foodworks, M&M Financial, Tata Consumer and Zee to announce results today.

Cadila Healthcare on Friday said its US arm Zydus Pharmaceuticals (USA) Inc has received tentative approval from the US health regulator to market generic Pimavanserin capsules, indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The approval by the US Food & Drug Administration for the generic Pimavanserin capsules is for the strength of 34 mg, Cadila Healthcare said in a regulatory filing. "The drug will be manufactured at the group's formulation manufacturing facility at SEZ Ahmedabad," it said. The group now has 325 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04, it added.

Cadila will provide manufacturing license and transfer the Plasmid DNA vaccine technology to Enzychem Lifesciences

The SGX Nifty indicates a quiet start for our markets this morning

Among sectors, the BSE Auto index jumped 1.3 per cent. The Capital Goods, Energy and Oil & Gas indices were also up around a per cent each. The Metal index, however, was down 0.8 per cent

ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus

The company's EBIDTA margin for the quarter was 22.7 per cent, up by 50 basis points